Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
Current NICE guidelines for type 2 diabetes (T2D) recommend identifying the most appropriate glucose-lowering therapy for a given individual. This decision depends not only on the initial glycaemic response, but also the durability of its glucose lowering effect over time. We investigated the latter...
| Glavni autori: | , , , , , |
|---|---|
| Format: | Conference item |
| Izdano: |
Springer
2017
|
| _version_ | 1826264986615283712 |
|---|---|
| author | Agbaje, O Coleman, R Hattersley, A Pearson, E Holman, R MASTERMIND Consortium |
| author_facet | Agbaje, O Coleman, R Hattersley, A Pearson, E Holman, R MASTERMIND Consortium |
| author_sort | Agbaje, O |
| collection | OXFORD |
| description | Current NICE guidelines for type 2 diabetes (T2D) recommend identifying the most appropriate glucose-lowering therapy for a given individual. This decision depends not only on the initial glycaemic response, but also the durability of its glucose lowering effect over time. We investigated the latter by examining possible predictors of post one-year durability for glucose-lowering monotherapies in people with new-onset T2D. |
| first_indexed | 2024-03-06T20:16:34Z |
| format | Conference item |
| id | oxford-uuid:2c56020d-f1d6-4a77-b3bb-e4bc18386d97 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T20:16:34Z |
| publishDate | 2017 |
| publisher | Springer |
| record_format | dspace |
| spelling | oxford-uuid:2c56020d-f1d6-4a77-b3bb-e4bc18386d972022-03-26T12:36:29ZPredicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetesConference itemhttp://purl.org/coar/resource_type/c_c94fuuid:2c56020d-f1d6-4a77-b3bb-e4bc18386d97Symplectic Elements at OxfordSpringer2017Agbaje, OColeman, RHattersley, APearson, EHolman, RMASTERMIND ConsortiumCurrent NICE guidelines for type 2 diabetes (T2D) recommend identifying the most appropriate glucose-lowering therapy for a given individual. This decision depends not only on the initial glycaemic response, but also the durability of its glucose lowering effect over time. We investigated the latter by examining possible predictors of post one-year durability for glucose-lowering monotherapies in people with new-onset T2D. |
| spellingShingle | Agbaje, O Coleman, R Hattersley, A Pearson, E Holman, R MASTERMIND Consortium Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes |
| title | Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes |
| title_full | Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes |
| title_fullStr | Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes |
| title_full_unstemmed | Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes |
| title_short | Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes |
| title_sort | predicting post one year durability of glucose lowering monotherapies in patients with new onset type 2 diabetes |
| work_keys_str_mv | AT agbajeo predictingpostoneyeardurabilityofglucoseloweringmonotherapiesinpatientswithnewonsettype2diabetes AT colemanr predictingpostoneyeardurabilityofglucoseloweringmonotherapiesinpatientswithnewonsettype2diabetes AT hattersleya predictingpostoneyeardurabilityofglucoseloweringmonotherapiesinpatientswithnewonsettype2diabetes AT pearsone predictingpostoneyeardurabilityofglucoseloweringmonotherapiesinpatientswithnewonsettype2diabetes AT holmanr predictingpostoneyeardurabilityofglucoseloweringmonotherapiesinpatientswithnewonsettype2diabetes AT mastermindconsortium predictingpostoneyeardurabilityofglucoseloweringmonotherapiesinpatientswithnewonsettype2diabetes |